Reviva Pharmaceuticals Holdings
Stock Forecast, Prediction & Price Target
Reviva Pharmaceuticals Holdings Financial Estimates
Reviva Pharmaceuticals Holdings Revenue Estimates
Reviva Pharmaceuticals Holdings EBITDA Estimates
Reviva Pharmaceuticals Holdings Earnings per Share Estimates
Passed | Analyst forecast | ||||||
---|---|---|---|---|---|---|---|
Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $220.44M Low: $220.44M High: $220.44M avg. 0% | Avg: $137.29M Low: $137.29M High: $137.29M avg. -37.71% | Avg: $249.43M Low: $249.43M High: $249.43M avg. 81.67% |
Net Income
% change YoY
| $-8.52M N/A | $-24.33M -185.60% | $-39.26T -161306305.29% | Avg: $-48.33M Low: $-20.88M High: $-13.85M avg. 99.99% | Avg: $-39.33M Low: $-19.90M High: $-5.07M avg. 18.62% | Avg: $13.07M Low: $13.07M High: $13.07M avg. 133.24% | Avg: $37.08M Low: $37.08M High: $37.08M avg. 183.58% |
EBITDA
% change YoY
| $-10.10M N/A | $-24.11M -138.62% | $-39.50T -163834511.28% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$0.58 N/A | -$1.25 -115.51% | -$1.65 -31.99% | Avg: -$0.89 Low: -$1.07 High: -$0.71 avg. 46.21% | Avg: -$0.64 Low: -$1.02 High: -$0.26 avg. 27.88% | Avg: $0.67 Low: $0.67 High: $0.67 avg. 204.68% | Avg: $1.9 Low: $1.9 High: $1.9 avg. 183.58% |
Operating Expenses
% change YoY
| $10.10M N/A | $24.30M 140.55% | $39.50T 162522107.95% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Reviva Pharmaceuticals Holdings stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 108.86% in 2025-2028.
We have gathered data from 3 analysts. Their low estimate is -20.88M, average is -48.33M and high is -13.85M.
What is Reviva Pharmaceuticals Holdings stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 10.99% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Reviva Pharmaceuticals Holdings stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 115.59% in 2025-2028.
We have gathered data from 3 analysts. Their low earnings per share estimate is -$1.07, average is -$0.89 and high is $-0.71.
What is the best performing analyst?
In the last twelve months analysts have been covering Reviva Pharmaceuticals Holdings stock. The most successful analyst is Raghuram Selvaraju.